Schedule 13D ownership disclosure

NEWAMSTERDAM PHARMA COMPANY

Ordinary Shares, Nominal value 0.12 per share · CUSIP: N62509109

Event date: 2025-09-26

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Forbion Capital Fund IV Cooperatief U.A.Reported CIK 0001823747

    Shares: 4,668,889 · Class: 4.1%

  • Forbion IV Management B.V.

    Shares: 4,668,889 · Class: 4.1%

  • Forbion Growth Opportunities Fund I Cooperatief U.A.

    Shares: 4,648,025 · Class: 4.1%

  • Forbion Growth Management B.V.

    Shares: 4,648,025 · Class: 4.1%

  • ForGrowth NAP B.V.

    Shares: 9,316,914 · Class: 8.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-25-225170
Form type
SCHEDULE 13D/A
Filer
Forbion Capital Fund IV Cooperatief U.A.
CIK
CIK 1823747
Filed
Sep 30, 2025
Reporting period
Sep 26, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub